Hydrazonoyl chlorides possess promising antitumor properties

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Drug Discovery

Background:

• Selective antitumor agents are crucial for effective cancer therapy.
• Hydrazonoyl chlorides (HCs) represent a class of compounds with potential biological activities.

Purpose of the Study:

• To identify novel selective antitumor agents from hydrazonoyl chloride derivatives.
• To evaluate the efficacy and molecular mechanisms of promising HCs against human cancer cells and in vivo tumor models.

Main Methods:

• Synthesis of various hydrazonoyl chlorides (HCs).
• Assessment of cytotoxicity against human tumor cell lines (HeLa, MCF7, HCT116) and non-tumor cells (CCD-18Co, splenocytes) using MTT assay.
• In vivo evaluation of tumor development inhibition in Ehrlich ascites carcinoma (EAC)-bearing mice.
• Molecular analyses including comet assay, cell cycle analysis, and investigation of PTEN, PNKP, and PI3K/AKT/mTOR pathway interactions.

Main Results:

• Two HCs, CPD 4 and CPD 5, exhibited significant cytotoxicity against cervical, breast, and colon cancer cells with minimal toxicity to normal cells.
• Active compounds demonstrated efficacy in inhibiting colony formation and tumor growth in vivo.
• PTEN-deficient cells showed increased sensitivity to HCs.
• Molecular studies revealed that HCs induce DNA damage and affect the PNKP and PI3K/AKT/mTOR pathway, suggesting a synthetic lethal interaction with PTEN.

Conclusions:

• Hydrazonoyl chlorides (HCs) demonstrate significant potential as hit compounds for developing new antitumor agents.
• The observed PTEN-dependent cytotoxicity and DNA damage induction provide a basis for further drug development strategies.